Neflamapimod Shows Exposure-Dependent NfL Reduction at 24 Weeks in nfvPPA
CRVO sits 30% above its 52-week low of $1.27.
Summary
CervoMed's 24-week Phase 2a data in nfvPPA show plasma NfL stayed flat overall in the 19 U.S. patients on 40 mg three times daily, and fell a median 4.5 pg/mL in the six patients whose trough drug levels reached at least 4.5 ng/ml. The other 12 patients, with trough levels at or below 3.5 ng/ml, saw NfL rise a median 4.35 pg/mL — roughly in line with the natural-history rate of about 9 pg/mL per year. That split is the point: the drug only looks active above a plasma threshold near 4 ng/ml, consistent with prior DLB and Alzheimer's work, and it supports the new 50 mg tablet designed to push nearly all patients above that level. This follows the 12-week biomarker readout in October and the September 8-K on the FDA lifting the exposure limit. The company still has substantial doubt about continuing as a going concern with $19.6 million in cash, so a DLB partnership remains the funding question. Full 24-week biomarker and clinical data, including the UK 80 mg twice-daily cohort, are due in the first quarter of 2027, with presentation at AD/PD in March 2027.
At the time of this announcement, CRVO was trading at $1.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $25.3M. The 52-week trading range was $1.27 to $10.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.